Toros Dincman, M.D., Ph.D.

 

Assistant Professor
Department: Hematology/Oncology
Programs: End Organ Disease

 

 

Research Interests:

Dr. Dincman received his AB from the University of Chicago, and his MD and PhD in Anatomical Sciences and Neurobiology from the University of Louisville. Following his Internal Medicine Residency , Hematology/Oncology fellowship training, and T32-funded postdoctoral training in Molecular Biology and Biochemistry at MUSC, Dr. Dincman joined the MUSC faculty in 2020.

Dr. Dincman’s research is broadly interested in the genomic, transcriptional, and post-transcriptional mechanisms mediating tumorigenesis, and their correlations to therapeutic response. Currently, his projects include the evaluation of the genomic and stromal features that are associated with clinical outcomes for pancreatic ductal adenocarcinoma (PDAC) following surgical resection. Dr. Dincman currently serves as the research lead for the GI disease focus group at Hollings Cancer Center.

Another principal project in the Dincman Lab is their focus on the association of Poly-(rC) Binding Protein 1 (PCBP1) with colorectal cancer (CRC) tumor development and their influence on CRC response to conventional therapies. PCBP1 mutations are frequently found in patients with genome-stable CRC and are associated with a more advanced primary tumor stage and the presence of high-risk clinical features. Ongoing research on PCBP1 is focused on determining the mechanistic ramifications of known PCBP1 tumor-associated mutations on the post-transcriptional regulation of target genes and cellular behavior such as cell proliferation, invasion, migration, cancer cell stemness, tumor progression in vivo in transgenic and syngeneic animal models.

Publications:

Pub Med Collection